Giancarlo Agnelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10426055/publications.pdf

Version: 2024-02-01

339 papers	43,860 citations	6233 80 h-index	2071 204 g-index
346 all docs	346 docs citations	346 times ranked	21912 citing authors

#	Article	IF	Citations
1	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	13.9	2,807
2	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
4	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	13.9	2,080
5	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 799-808.	13.9	1,915
6	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 2008, 133, 454S-545S.	0.4	1,860
7	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	13.9	1,221
8	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 2004, 126, 401S-428S.	0.4	1,216
9	Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2013, 368, 699-708.	13.9	1,116
10	Venous thromboembolism (VTE) in Europe. Thrombosis and Haemostasis, 2007, 98, 756-764.	1.8	1,100
11	Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. New England Journal of Medicine, 2002, 346, 975-980.	13.9	973
12	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 2001, 119, 176S-193S.	0.4	945
13	Short-Term Clinical Outcome of Patients With Acute Pulmonary Embolism, Normal Blood Pressure, and Echocardiographic Right Ventricular Dysfunction. Circulation, 2000, 101, 2817-2822.	1.6	785
14	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 2020, 382, 1599-1607.	13.9	658
15	Prognostic Value of Troponins in Acute Pulmonary Embolism. Circulation, 2007, 116, 427-433.	1.6	653
16	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. Annals of Surgery, 2006, 243, 89-95.	2.1	595
17	Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. Circulation, 2004, 110, 744-749.	1.6	578
18	Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. New England Journal of Medicine, 2001, 345, 165-169.	13.9	567

#	Article	IF	Citations
19	Aspirin for Preventing the Recurrence of Venous Thromboembolism. New England Journal of Medicine, 2012, 366, 1959-1967.	13.9	545
20	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology, The, 2009, 10, 943-949.	5.1	538
21	Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients. Journal of Clinical Oncology, 2003, 21, 3665-3675.	0.8	531
22	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis, 2007, 98, 756-64.	1.8	531
23	Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery. New England Journal of Medicine, 1998, 339, 80-85.	13.9	522
24	Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. New England Journal of Medicine, 2012, 366, 601-609.	13.9	489
25	Critical Issues in Peripheral Arterial Disease Detection and Management<subtitle>A Call to Action</subtitle>. Archives of Internal Medicine, 2003, 163, 884.	4.3	486
26	Acute Pulmonary Embolism. New England Journal of Medicine, 2010, 363, 266-274.	13.9	423
27	Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome. Stroke, 2008, 39, 2249-2256.	1.0	416
28	Incidence of Chronic Thromboembolic Pulmonary Hypertension After a First Episode of Pulmonary Embolism. Chest, 2006, 130, 172-175.	0.4	377
29	Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism. Annals of Internal Medicine, 2003, 139, 19.	2.0	344
30	PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-526.	1.2	337
31	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939). Circulation, 2007, 116, 180-187.	1.6	324
32	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. Blood, 2008, 112, 2242-2247.	0.6	316
33	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ: British Medical Journal, 2011, 342, d3036-d3036.	2.4	315
34	Rivaroxaban. Clinical Pharmacokinetics, 2011, 50, 675-686.	1.6	301
35	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Internal and Emergency Medicine, 2012, 7, 291-292.	1.0	299
36	Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients. Journal of Clinical Oncology, 2005, 23, 4057-4062.	0.8	293

#	Article	IF	Citations
37	Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke. Stroke, 2007, 38, 423-430.	1.0	286
38	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. European Heart Journal, 2018, 39, 4208-4218.	1.0	267
39	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and Haemostasis, 2003, 89, 288-296.	1.8	256
40	Direct Oral Anticoagulants in Patients With VTE and Cancer. Chest, 2015, 147, 475-483.	0.4	253
41	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 32-67.	1.0	243
42	Aspirin for the Prevention of Recurrent Venous Thromboembolism. Circulation, 2014, 130, 1062-1071.	1.6	232
43	Venous thrombosis. Nature Reviews Disease Primers, 2015, 1, 15006.	18.1	216
44	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation. Stroke, 2015, 46, 2175-2182.	1.0	213
45	Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis. Annals of Internal Medicine, 2009, 150, 577.	2.0	209
46	Prevention of Venous Thromboembolism in Surgical Patients. Circulation, 2004, 110, IV-4-IV-12.	1.6	207
47	Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery. Archives of Internal Medicine, 2000, 160, 2327.	4.3	204
48	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 2016, 48, 780-786.	3.1	199
49	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. European Heart Journal, 2011, 32, 1657-1663.	1.0	188
50	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 1998, 114, 561S-578S.	0.4	184
51	Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis. Chest, 1994, 106, 718-724.	0.4	182
52	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ: British Medical Journal, 2019, 366, l4363.	2.4	177
53	Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement. Circulation, 2001, 104, 74-78.	1.6	170
54	A prospective study on cardiovascular events after acute pulmonary embolism. European Heart Journal, 2005, 26, 77-83.	1.0	168

#	Article	IF	Citations
55	Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thrombosis Research, 2010, 125, e82-e86.	0.8	168
56	A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer. Annals of Surgery, 2014, 259, 665-669.	2.1	162
57	Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. European Respiratory Journal, 2014, 43, 1678-1690.	3.1	144
58	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. British Journal of Haematology, 2005, 129, 811-817.	1.2	134
59	Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thrombosis Research, 2012, 130, 847-852.	0.8	129
60	Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism. Archives of Internal Medicine, 2002, 162, 2537.	4.3	124
61	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica, 2008, 93, 273-278.	1.7	123
62	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. European Heart Journal, 2007, 28, 1717-1722.	1.0	121
63	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and Haemostasis, 2018, 118, 1668-1678.	1.8	121
64	The Concept of Ischemic Penumbra in Acute Stroke and Therapeutic Opportunities. European Neurology, 2009, 61, 321-330.	0.6	120
65	Neuroimaging in Intracerebral Hemorrhage. Stroke, 2014, 45, 903-908.	1.0	113
66	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. American Journal of Cardiology, 1998, 82, 1230-1235.	0.7	109
67	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis, 2020, 293, 94-100.	0.4	109
68	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Internal and Emergency Medicine, 2008, 3, 117-122.	1.0	106
69	Association of Persistent Right Ventricular Dysfunction at Hospital Discharge After Acute Pulmonary Embolism With Recurrent Thromboembolic Events. Archives of Internal Medicine, 2006, 166, 2151.	4.3	101
70	Edoxaban: a focused review of its clinical pharmacology. European Heart Journal, 2014, 35, 1844-1855.	1.0	99
71	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 1128-1136.	1.8	93
72	Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica, 2007, 92, 812-818.	1.7	92

#	Article	IF	Citations
73	A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. Thrombosis and Haemostasis, 1992, 67, 203-208.	1.8	90
74	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine, 2011, 9, 179.	1.8	90
75	Multidetector CT Scan for Acute Pulmonary Embolism. Chest, 2012, 142, 1417-1424.	0.4	90
76	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Nonâ€“Vitaminâ€K Oral Anticoagulants (RAFâ€NOACs) Study. Journal of the American Heart Association, 2017, 6, .	1.6	89
77	Systemic Thrombolysis in Patients With Acute Ischemic Stroke and Internal Carotid ARtery Occlusion. Stroke, 2012, 43, 125-130.	1.0	86
78	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Annals of Neurology, 2019, 85, 823-834.	2.8	84
79	What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?. Thrombosis Research, 2007, 119, 265-274.	0.8	82
80	Outcome in Patients with Stroke Associated with Internal Carotid Artery Occlusion. Cerebrovascular Diseases, 2005, 20, 108-113.	0.8	81
81	Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers. Thrombosis and Haemostasis, 2002, 87, 947-952.	1.8	79
82	The MASTER registry on venous thromboembolism: Description of the study cohort. Thrombosis Research, 2008, 121, 605-610.	0.8	79
83	The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits. Thrombosis and Haemostasis, 1990, 63, 204-207.	1.8	77
84	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. Chest, 2016, 149, 192-200.	0.4	76
85	Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke. Cerebrovascular Diseases, 2009, 28, 119-123.	0.8	74
86	The management of acute venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 2017, 117, 1326-1337.	1.8	74
87	Acute Pulmonary Embolism: External Validation of an Integrated Risk Stratification Model. Chest, 2013, 144, 1539-1545.	0.4	71
88	Novel approaches to the treatment of thrombosis. Trends in Pharmacological Sciences, 2002, 23, 25-32.	4.0	67
89	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 2020, 51, 3504-3513.	1.0	67
90	Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer. Thrombosis and Haemostasis, 1999, 82, 30-34.	1.8	64

#	Article	IF	Citations
91	Treatment of Venous Thromboembolism With New Anticoagulant Agents. Journal of the American College of Cardiology, 2016, 67, 1941-1955.	1.2	63
92	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist, 2018, 23, 247-255.	1.9	63
93	Statins and Stroke Prevention. Cerebrovascular Diseases, 2007, 24, 170-182.	0.8	61
94	D-Dimer for risk stratification in patients with acute pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2012, 33, 48-57.	1.0	61
95	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
96	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	2.0	60
97	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2019, 50, 2168-2174.	1.0	59
98	Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 781-783.	13.9	59
99	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and Haemostasis, 2003, 89, 288-96.	1.8	59
100	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits. Thrombosis Research, 1985, 40, 769-777.	0.8	58
101	Treatment of DVT: how long is enough and how do you predict recurrence. Journal of Thrombosis and Thrombolysis, 2008, 25, 37-44.	1.0	58
102	Intravenous Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Aged Older than 80 Years in Italy. Cerebrovascular Diseases, 2008, 25, 129-135.	0.8	57
103	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thrombosis Research, 2012, 129, 392-400.	0.8	56
104	Clinically Overt Venous Thromboembolism after Urologic Cancer Surgery: Results from the @RISTOS Study. European Urology, 2007, 51, 130-136.	0.9	55
105	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. Journal of the American Heart Association, 2018, 7, e010133.	1.6	55
106	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and Haemostasis, 2021, 121, 616-624.	1.8	55
107	Gender Differences in Patients with Acute Ischemic Stroke. Women's Health, 2010, 6, 51-57.	0.7	54
108	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thrombosis Research, 2005, 116, 301-306.	0.8	52

#	Article	IF	Citations
109	Rationale for Bolus t-PA Therapy To Improve Efficacy and Safety. Chest, 1990, 97, 161S-167S.	0.4	50
110	Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis. Thrombosis Research, 2014, 134, 1265-1271.	0.8	47
111	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. International Journal of Cardiology, 2017, 227, 261-266.	0.8	47
112	Obesity and the Risk of Intracerebral Hemorrhage. Stroke, 2013, 44, 1584-1589.	1.0	46
113	Aspirin for prevention and treatment of venous thromboembolism. Blood Reviews, 2014, 28, 103-108.	2.8	46
114	Venous Thromboembolism and Gancer: a Two-Way Clinical Association. Thrombosis and Haemostasis, 1997, 78, 117-120.	1.8	46
115	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. Thrombosis Research, 2018, 165, 33-37.	0.8	45
116	Admission Leukocytosis in Acute Cerebral Ischemia: Influence on Early Outcome. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 819-824.	0.7	44
117	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44
118	Effect of On-Admission Antiplatelet Treatment on Patients with Cerebral Hemorrhage. Cerebrovascular Diseases, 2007, 24, 215-218.	0.8	43
119	Risk of Recurrent Cerebrovascular Events in Patients with Cryptogenic Stroke or Transient Ischemic Attack and Patent Foramen Ovale: The FORI (Foramen Ovale Registro Italiano) Study. Cerebrovascular Diseases, 2011, 31, 109-116.	0.8	43
120	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. Journal of Neurology, 2015, 262, 459-468.	1.8	43
121	Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nature Clinical Practice Oncology, 2006, 3, 214-222.	4.3	40
122	The management of acute venous thromboembolism in clinical practice â€“ study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	0.9	40
123	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. European Heart Journal, 2021, 42, 3190-3199.	1.0	40
124	Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thrombosis Research, 2015, 136, 924-927.	0.8	39
125	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thrombosis and Haemostasis, 2016, 116, 410-416.	1.8	39
126	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	1.5	38

#	Article	IF	Citations
127	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer, 2021, 148, 371-381.	1.3	38
128	Prevention of Venous Thromboembolism. Thrombosis Research, 2000, 97, V49-V62.	0.8	37
129	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis, 2010, 212, 564-566.	0.4	37
130	Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. Thrombosis and Haemostasis, 1996, 76, 0887-0892.	1.8	37
131	Seasonal Variation in the Occurrence of Venous Thromboembolism: Data From the MASTER Registry. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 309-315.	0.7	35
132	Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. International Journal of Cardiology, 2018, 269, 152-157.	0.8	35
133	Recurrent Venous Thromboembolism in Men and Women. New England Journal of Medicine, 2004, 351, 2015-2018.	13.9	33
134	Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. Thrombosis Research, 2012, 130, 369-373.	0.8	33
135	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 924-929.	0.9	33
136	Epidemiology of Cerebral Vein and Sinus Thrombosis. , 2007, 23, 16-22.		32
137	Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. Journal of Neurology, 2012, 259, 106-110.	1.8	32
138	Antithrombotic medications and the etiology of intracerebral hemorrhage. Neurology, 2014, 82, 529-535.	1.5	32
139	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. Journal of Neurology, 2016, 263, 231-237.	1.8	32
140	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. Stroke, 2017, 48, 726-732.	1.0	32
141	Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients. Thrombosis and Haemostasis, 1992, 68, 257-260.	1.8	32
142	Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation, 1995, 92, 2819-2824.	1.6	32
143	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. Thrombosis Research, 2018, 170, 175-180.	0.8	31
144	Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery. Annals of Surgery, 2014, 259, 1073-1079.	2.1	30

#	Article	IF	Citations
145	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€VTE patients. Journal of Thrombosis and Haemostasis, 2019, 17, 1694-1706.	1.9	30
146	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open, 2017, 2, e000188.	2.0	29
147	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	0.8	29
148	Anticoagulation After Stroke in Patients With Atrial Fibrillation. Stroke, 2019, 50, 2093-2100.	1.0	29
149	Acute treatment of venous thromboembolism. Blood, 2020, 135, 305-316.	0.6	29
150	Dermatan sulphate in heparin-induced thrombocytopenia. Lancet, The, 1994, 344, 1295-1296.	6.3	28
151	96Âhours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. Internal and Emergency Medicine, 2014, 9, 65-67.	1.0	28
152	Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). Thrombosis and Haemostasis, 2016, 116, 349-355.	1.8	28
153	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	28
154	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€"Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038.	1.8	28
155	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke, 2022, 53, 2620-2627.	1.0	28
156	A prospective study on survival in cancer patients with and without venous thromboembolism. Internal and Emergency Medicine, 2014, 9, 559-67.	1.0	27
157	Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2017, 236, 363-369.	0.8	27
158	Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 1217-1228.	1.9	27
159	Risk stratification and management of acute pulmonary embolism. Hematology American Society of Hematology Education Program, 2016, 2016, 404-412.	0.9	26
160	Practical â€œ1-2-3-4-Dayâ€•Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke, 2022, 53, 1540-1549.	1.0	26
161	Bolus Thrombolysis in Venous Thromboembolism. Chest, 1992, 101, 172S-182S.	0.4	25
162	Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagulation and Fibrinolysis, 2008, 19, 663-667.	0.5	25

#	Article	IF	Citations
163	Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. Journal of Diabetes and Its Complications, 2012, 26, 70-76.	1.2	25
164	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	1.8	25
165	A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study. Blood, 2008, 112, 6-6.	0.6	25
166	DESMOPRESSIN-INDUCED IMPROVEMENT OF ABNORMAL COAGULATION IN CHRONIC LIVER DISEASE. Lancet, The, 1983, 321, 645.	6.3	23
167	Current Issues in Anticoagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 2-9.	0.5	23
168	New anticoagulants for the prevention of venous thromboembolism. Drug Design, Development and Therapy, 2010, 4, 49.	2.0	23
169	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Internal and Emergency Medicine, 2017, 12, 1291-1305.	1.0	23
170	Patients aged 90â€¯years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. International Journal of Cardiology, 2019, 281, 56-61.	0.8	23
171	Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. International Journal of Cardiology, 2020, 301, 167-172.	0.8	23
172	Intravenous Thrombolysis for Acute Ischemic Stroke Associated to Extracranial Internal Carotid Artery Occlusion: The ICARO-2 Study. Cerebrovascular Diseases, 2012, 34, 430-435.	0.8	22
173	The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. Journal of Surgical Oncology, 2007, 96, 265-272.	0.8	21
174	Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: Independent predictors of poor outcome at three months. European Journal of Internal Medicine, 2013, 24, 310-313.	1.0	21
175	Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. European Respiratory Journal, 2015, 45, 1142-1149.	3.1	21
176	Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. Haematologica, 2020, 105, 838-848.	1.7	21
177	Definition of major bleeding: Prognostic classification. Journal of Thrombosis and Haemostasis, 2020, 18, 2852-2860.	1.9	21
178	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	2.2	21
179	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Thrombosis and Haemostasis, 2022, 122, 796-807.	1.8	21
180	Clinical Outcome of Orthopaedic Patients with Negative Lower Limb Venography at Discharge. Thrombosis and Haemostasis, 1995, 74, 1042-1044.	1.8	21

#	Article	IF	Citations
181	Need for extensive diagnostic work-up for patients with lacunar stroke. Journal of Neurology, 2008, 255, 637-642.	1.8	20
182	Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e26-e31.	0.8	20
183	Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 471-477.	0.9	20
184	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologica, 2015, 100, e35-e38.	1.7	20
185	Alcohol intake and the risk of intracerebral hemorrhage in the elderly. Neurology, 2018, 91, e227-e235.	1.5	20
186	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 439-453.	1.0	20
187	Safety of catheter ablation of atrial fibrillation in cancer survivors. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 419-426.	0.6	20
188	Risk Factors for Adverse Short-Term Outcome in Patients with Pulmonary Embolism. Thrombosis Research, 2001, 103, V239-V244.	0.8	19
189	New oral anticoagulants for the treatment ofÂvenous thromboembolism. Best Practice and Research in Clinical Haematology, 2013, 26, 151-161.	0.7	19
190	Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine, 2015, 10, 651-656.	1.0	19
191	Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis, 2018, 271, 177-181.	0.4	19
192	Longâ€term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	1.9	19
193	A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. Thrombosis and Haemostasis, 2008, 99, 241-244.	1.8	18
194	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. Clinical Drug Investigation, 2021, 41, 43-51.	1.1	18
195	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis, 2021, 19, 2751-2759.	1.9	18
196	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. TH Open, 2021, 05, e376-e386.	0.7	18
197	Anticoagulation in the Prevention and Treatment of Pulmonary Embolism. Chest, 1995, 107, 39S-44S.	0.4	17
198	Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery. Clinical Drug Investigation, 2005, 25, 65-77.	1.1	17

#	Article	IF	Citations
199	Non-neurological complications of acute stroke: frequency and influence on clinical outcome. Internal and Emergency Medicine, 2011, 6, 119-123.	1.0	17
200	The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?. Blood, 2014, 124, 155-156.	0.6	17
201	Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. Journal of Thrombosis and Thrombolysis, 2016, 42, 336-339.	1.0	17
202	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. European Journal of Internal Medicine, 2020, 75, 35-43.	1.0	17
203	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. JAMA Neurology, 2021, 78, 177.	4.5	17
204	A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR.. Blood, 2005, 106, 278-278.	0.6	17
205	Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research, 2010, 125, S17-S20.	0.8	16
206	Efficacy and safety of direct oral anticoagulants after pulmonary embolism: A meta-analysis. International Journal of Cardiology, 2014, 177, 601-603.	0.8	16
207	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis, 2016, 115, 809-816.	1.8	16
208	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis, 2016, 116, 1159-1164.	1.8	16
209	The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. Clinical Cardiology, 2019, 42, 1147-1154.	0.7	16
210	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. Journal of Thrombosis and Thrombolysis, 2020, 49, 251-258.	1.0	16
211	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. Thrombosis and Haemostasis, 2008, 99, 978-980.	1.8	15
212	New and old anticoagulants in cancer. Thrombosis Research, 2012, 129, S101-S105.	0.8	15
213	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	0.9	15
214	Combined oral anticoagulants and antiplatelets: benefits and risks. Internal and Emergency Medicine, 2010, 5, 281-290.	1.0	14
215	Lung ultrasound in the diagnosis of stroke-associated pneumonia. Internal and Emergency Medicine, 2014, 9, 173-178.	1.0	14
216	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. European Journal of Internal Medicine, 2016, 33, 42-46.	1.0	14

#	Article	IF	Citations
217	The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach. PLoS ONE, 2018, 13, e0195805.	1.1	14
218	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. Cancer Treatment Reviews, 2021, 96, 102190.	3.4	14
219	Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935). Thrombosis and Haemostasis, 1993, 70, 294-300.	1.8	14
220	Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica, 2005, 90, 154-6.	1.7	14
221	Initial treatment of venous thromboembolism. Thrombosis and Haemostasis, 2006, 96, 242-250.	1.8	13
222	Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins. Expert Review of Molecular Diagnostics, 2008, 8, 339-349.	1.5	13
223	Prognostic value of respiratory index in haemodynamically stable patients with acute pulmonary embolism: The Respiratory Index model study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 286-292.	0.4	13
224	SMASH-U classification: a tool for aetiology-oriented management of patients with acute haemorrhagic stroke. Internal and Emergency Medicine, 2021, 16, 109-114.	1.0	13
225	Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. Vascular Health and Risk Management, 2007, 3, 749-54.	1.0	13
226	Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica, 2002, 87, 757-70.	1.7	13
227	Dermatan sulphate in patients with heparin-induced thrombocytopenia. British Journal of Haematology, 1999, 104, 87-89.	1.2	12
228	Clinical Benefit of Early Anticoagulation in Cardioembolic Stroke. Cerebrovascular Diseases, 2008, 25, 289-296.	0.8	12
229	Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 585-588.	1.8	12
230	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. Internal and Emergency Medicine, 2015, 10, 595-601.	1.0	12
231	Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. Blood Transfusion, 2018, 16, 387-391.	0.3	12
232	Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. Clinical Pharmacokinetics, 1997, 32, 145-172.	1.6	11
233	Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. Seminars in Hematology, 2001, 38, 58-66.	1.8	11
234	New Anticoagulants. Seminars in Thrombosis and Hemostasis, 2006, 32, 793-802.	1.5	11

#	Article	IF	Citations
235	Right ventricle dysfunction in patients with pulmonary embolism. Internal and Emergency Medicine, 2010, 5, 453-455.	1.0	11
236	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. Internal and Emergency Medicine, 2013, 8, 575-580.	1.0	11
237	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. Internal and Emergency Medicine, 2015, 10, 555-560.	1.0	11
238	Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?. Internal and Emergency Medicine, 2016, 11, 817-824.	1.0	11
239	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis, 2019, 119, 461-466.	1.8	11
240	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. European Journal of Cancer, 2022, 165, 136-145.	1.3	11
241	Acute Stroke Symptoms: Do Differences Exist between Sexes?. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2928-2933.	0.7	10
242	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thrombosis Research, 2017, 157, 181-188.	0.8	10
243	Bedside sonography assessment of extravascular lung water increase after major pulmonary resection in non-small cell lung cancer patients. Journal of Thoracic Disease, 2018, 10, 4077-4084.	0.6	10
244	Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. Cardiovascular Drugs and Therapy, 2021, 35, 987-993.	1.3	10
245	Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis. Neurological Sciences, 2020, 41, 2503-2509.	0.9	10
246	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. European Journal of Internal Medicine, 2021, 88, 43-51.	1.0	10
247	Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. International Journal of Cardiology, 2021, 339, 158-163.	0.8	10
248	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 100, 102280.	3.4	10
249	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. Thrombosis and Haemostasis, 1981, 46, 572-572.	1.8	10
250	Direct Thrombin Inhibitors for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. Current Pharmaceutical Design, 2005, 11, 3885-3891.	0.9	9
251	Attitudes to prescribing compression stockings for patients with acute dvt: the MASTER registry. Journal of Thrombosis and Thrombolysis, 2009, 28, 389-393.	1.0	9
252	New strategies of VTE prevention in cancer patients. Thrombosis Research, 2014, 133, S128-S132.	0.8	9

#	Article	IF	Citations
253	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 2017, 49, 1601732.	3.1	9
254	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. Journal of Thrombosis and Thrombolysis, 2017, 44, 527-535.	1.0	9
255	The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, 2018, 46, 507-515.	1.0	9
256	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 2019, 28, 1155-1177.	1.5	9
257	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 692-701.	1.8	9
258	Experimental Pharmacology of Hirunorm: a Novel Synthetic Peptide Thrombin Inhibitor. Thrombosis and Haemostasis, 1996, 76, 384-392.	1.8	9
259	Thromboprophylaxis during chemotherapy after advanced cancer. Thrombosis Research, 2007, 120, S128-S132.	0.8	8
260	Low Levels of Low-Density Lipoprotein Cholesterol Increase Hemorrhagic Transformation but Not Parenchimal Hematoma in Large Artery Atherothrombosisis. Stroke, 2009, 40, e544; author reply e545.	1.0	8
261	Edoxaban in Atrial Fibrillation and Venous Thromboembolismâ€"Ten Key Questions and Answers: A Practical Guide. Advances in Therapy, 2017, 34, 620-637.	1.3	8
262	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. European Journal of Internal Medicine, 2020, 72, 53-59.	1.0	8
263	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. Annals of Neurology, 2022, 91, 78-88.	2.8	8
264	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. Seminars in Thrombosis and Hemostasis, 2015, 41, 113-132.	1.5	7
265	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1363-1368.	0.7	7
266	Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management. European Journal of Internal Medicine, 2020, 82, 18-20.	1.0	7
267	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke, 2020, 51, 2347-2354.	1.0	7
268	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Nonâ€"Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	1.0	7
269	Optimal Dosage Regimens of Tissue-Type Plasminogen Activator. Seminars in Thrombosis and Hemostasis, 1987, 13, 160-162.	1.5	6
270	End Points in Studies on the Prevention of Deep Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 2001, 27, 041-046.	1.5	6

#	Article	IF	Citations
271	Clinical Potential of Oral Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. Drugs, 2004, 64, 47-52.	4.9	6
272	Assessment of Bleeding after Concomitant Administration of Antiplatelet and Anticoagulant Agents in Lower Limb Arthroplasty. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 428-434.	0.5	6
273	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thrombosis and Haemostasis, 2009, 101, 596-598.	1.8	6
274	The year in cardiology 2016: peripheral circulation. European Heart Journal, 2017, 38, ehw643.	1.0	6
275	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	0.8	6
276	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. JNCI Cancer Spectrum, 2017, 1, pkx009.	1.4	6
277	Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. Internal and Emergency Medicine, 2020, 15, 429-436.	1.0	6
278	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. European Stroke Journal, 2020, 5, 374-383.	2.7	6
279	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. Thrombosis and Haemostasis, 1993, 70, 443-447.	1.8	6
280	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. Thrombosis Research, 2021, 208, 138-144.	0.8	6
281	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. Trends in Cardiovascular Medicine, 2023, 33, 336-343.	2.3	6
282	Thromboprophylaxis in Acutely Ill Medical Patients: Results of A Survey Among Italian Physicians. Thrombosis Research, 2014, 134, 572-577.	0.8	5
283	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. Internal and Emergency Medicine, 2016, 11, 1095-1102.	1.0	5
284	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. European Journal of Internal Medicine, 2019, 69, 1-7.	1.0	5
285	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	1.0	5
286	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	0.8	5
287	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients â€“ PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. European Neurology, 2020, 83, 566-575.	0.6	5
288	A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke. European Stroke Journal, 2020, 5, 384-393.	2.7	5

#	Article	IF	Citations
289	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. Cerebrovascular Diseases Extra, 2020, 10, 44-49.	0.5	5
290	Home management or hospital admission for low-risk pulmonary embolism? Clinical scores versus pragmatic assessment. European Heart Journal, 2021, 42, 3158-3160.	1.0	5
291	The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 94, 45-55.	1.0	5
292	Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. Journal of Medical Economics, 2022, 25, 840-847.	1.0	5
293	Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. International Journal of Cardiology, 1995, 49, S77-S87.	0.8	4
294	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		4
295	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. Expert Opinion on Drug Safety, 2018, 17, 1063-1069.	1.0	4
296	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. International Journal of Cardiology, 2018, 269, 75-79.	0.8	4
297	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. European Stroke Journal, 2019, 4, 55-64.	2.7	4
298	Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study. Thrombosis and Haemostasis, 2019, 119, 2043-2052.	1.8	4
299	Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials. International Journal of Stroke, 2021, 16, 43-54.	2.9	4
300	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience, 2020, 14, 998.	0.6	4
301	Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.. Blood, 2007, 110, 309-309.	0.6	4
302	Contemporary clinical management of acute pulmonary embolism: the COPE study. Internal and Emergency Medicine, 2022, 17, 715-723.	1.0	4
303	Medicine before and after David Cox. European Journal of Internal Medicine, 2022, 98, 1-3.	1.0	4
304	FACTOR-VIIcoagKINETICS IN FACTOR-VII-CRM+AND FACTOK- VII-CKM-DEFICIENCIES. British Journal of Haematology, 1980, 46, 307-309.	1.2	3
305	Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications. Seminars in Thrombosis and Hemostasis, 1994, 20, 266-273.	1.5	3
306	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. Italian Journal of Medicine, 0, , .	0.2	3

#	Article	IF	Citations
307	Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 094-106.	0.8	3
308	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism. Blood Coagulation and Fibrinolysis, 2018, 29, 391-394.	0.5	3
309	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thrombosis and Haemostasis, 2021, 0, .	1.8	3
310	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. Thrombosis Research, 2018, 164, S168-S171.	0.8	2
311	Clinical skills or high-tech MR in TIA patients: what makes the difference?. Neurological Sciences, 2018, 39, 2091-2096.	0.9	2
312	Diagnosis and Treatment of Deep Vein Thrombosis in the Emergency Department: Results of an Italian Nominal Group Technique Study. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095972.	0.7	2
313	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. Life, 2021, 11, 395.	1.1	2
314	New strategies for enhancing the speed and rate of coronary reperfusion. American Journal of Cardiology, 1993, 72, G51-G58.	0.7	1
315	Unresolved Issues in the Prevention and Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2002, 28, 033-040.	1.5	1
316	Reply to Letter. Annals of Surgery, 2015, 262, e123-e124.	2.1	1
317	Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No. Internal and Emergency Medicine, 2015, 10, 281-284.	1.0	1
318	Reply to Letter. Annals of Surgery, 2016, 263, e63.	2.1	1
319	Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study. TH Open, 2019, 03, e157-e164.	0.7	1
320	Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation. Data in Brief, 2019, 23, 103794.	0.5	1
321	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. Thrombosis Research, 2020, 191, S123-S127.	0.8	1
322	Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes. Internal and Emergency Medicine, 2017, 12, 573-576.	1.0	1
323	Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study. Blood, 2016, 128, 1422-1422.	0.6	1
324	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. European Journal of Internal Medicine, 2021, , .	1.0	1

#	Article	IF	Citations
325	Duration of Anticoagulant Treatment after VenousThromboembolism. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 354-357.	0.5	0
326	Response to Letter by Guedes and Ferro. Stroke, 2008, 39, .	1.0	0
327	Thrombolysis for the Treatment of Pulmonary Embolism. , 0, , 503-512.		0
328	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. PiÃ¹ luci che ombre. Italian Journal of Medicine, 2012, 6, 153-169.	0.2	0
329	Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use). Current Vascular Pharmacology, 2014, 12, 351-352.	0.8	0
330	Risk of death in patients with major bleedings while on treatment with oral anticoagulants. International Journal of Cardiology, 2017, 235, 200.	0.8	0
331	Antithrombotic Cancer Associated Thrombosis: It May Change. Journal of Blood & Lymph, 2018, s1, .	0.0	0
332	Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the â€˜Letter to the Editorâ€™ from Dr. Sorigue et al.. International Journal of Cardiology, 2019, 280, 97.	0.8	0
333	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. Thrombosis and Haemostasis, 2021, 121, 700-702.	1.8	0
334	Non-Anticoagulant Actions of Glycosaminoglycans. , 1996, , 101-112.		0
335	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. Minerva Medica, 2020, 111, 370-372.	0.3	0
336	Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 672.	0.5	0
337	Long-term therapy of pulmonary embolism. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 824-9.	0.1	0
338	341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. European Heart Journal Supplements, 2021, 23, .	0.0	0
339	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica, 2021, , .	1.7	0